Biotech Values

[genisi]

Hisamitsu has proposed to acquire Noven for total cash consideration of approximately $428 million, or $16.50 per share, in an all-cash tender offer for 100% of the outstanding shares of Noven. The offer price represents a 22% premium to the closing price of Noven’s common stock on July 13, 2009

http://www.thestreet.com/_yahoo/story/10542447/1/hisamitsu-to-buy-noven-for-428m-noven-soars.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA